Healthcare
Immix Biopharma, Inc.(IMMX)
Live Price
Offline$8.45
+4.32% today
1Y Change
+353.27%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $470.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -17.1%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immix Biopharma, Inc. (IMMX) is a Healthcare stock with a market cap of $470.00M and listed on NASDAQ. The stock last traded around $8.45 and up 353.3% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -17.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -17.1%, free cash flow -56.4% with operating margin 0.0% and ROIC -31.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines IMMX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 3, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -17.1%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +9.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 3, 2026 | โ | -0.2% | -3.1% | โ |
2026 Mar 25, 2026 | -28.6% | -2.1% | -3.3% | +14.1% |
2025 Nov 7, 2025 | -26.3% | +2.9% | +33.7% | +95.2% |
Benchmark Edge
IMMX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IMMX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IMMX Max Drawdown
-39.84%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IMMX and SPY.
Company Overview
Immix Biopharma, Inc.
NASDAQ Capital Market
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
- Leadership
- Ilya Rachman
- IPO Date
- Dec 16, 2021
- Employees
- 18
- Street Address
- 11400 West Olympic Boulevard
- Mailing
- Los Angeles, CA, 90064
- Region
- Los Angeles, CA, US
- Reporting Currency
- USD
- Investor Line
- 310 651 8041
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.6
Growth
- Revenue
- 0.0%
- EPS
- -17.1%
- Free Cash Flow
- -56.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -101.2%
- ROIC
- -31.6%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 10.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.